M&A Considerations Across the Evolving Life Sciences Sector

The life sciences M&A landscape in the first quarter of 2026 was defined by constrained capital markets, heightened investor selectivity, and increasingly sophisticated transaction structures. With a slow IPO market and traditional financing sources limited, companies turned to alternative capital solutions and innovative deal frameworks to advance pipelines and achieve strategic objectives.... By: Morgan Lewis